Sinclair Pharma Limited Sustainability Profile
Sinclair Pharma Limited, a prominent player in the global aesthetics and dermatology industry, is headquartered in Great Britain. Founded in 1971, the company has established itself as a leader in innovative medical solutions, focusing on advanced products for skin health and aesthetic enhancement. With a strong presence in Europe, Asia, and the Americas, Sinclair Pharma is renowned for its unique offerings, including injectable fillers and skin rejuvenation treatments. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in the market. Sinclair Pharma's core products, such as the well-regarded Ellansé and Silhouette Soft, are distinguished by their long-lasting results and biocompatibility. With a reputation for quality and innovation, Sinclair Pharma continues to make strides in the aesthetic sector, contributing to the evolving landscape of cosmetic medicine.
DitchCarbon Score
How does Sinclair Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinclair Pharma Limited's score of 30 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinclair Pharma Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Huadong Medicine Co., Ltd, which may influence its climate-related initiatives and reporting practices. Despite the lack of direct emissions data, Sinclair Pharma Limited's climate commitments and reduction initiatives are not explicitly outlined. The company does not appear to have set specific reduction targets or participate in initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) at this time. As a subsidiary, Sinclair Pharma Limited may align its sustainability efforts with those of its parent company, Huadong Medicine Co., Ltd, which could include broader industry practices and commitments to reducing carbon footprints. However, without specific data or targets, the company's individual climate strategy remains unclear. In summary, while Sinclair Pharma Limited is part of a larger corporate structure that may have climate commitments, it currently lacks publicly available emissions data and defined reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 11,305,600 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Sinclair Pharma Limited's Industry?
How Carbon Intensive is Sinclair Pharma Limited's Location?
Sinclair Pharma Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sinclair Pharma Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
